Connor Clark & Lunn Investment Management Ltd. Takes $870,000 Position in USANA Health Sciences, Inc. $USNA

Connor Clark & Lunn Investment Management Ltd. bought a new position in USANA Health Sciences, Inc. (NYSE:USNA - Free Report) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 32,269 shares of the company's stock, valued at approximately $870,000. Connor Clark & Lunn Investment Management Ltd. owned 0.17% of USANA Health Sciences as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. PNC Financial Services Group Inc. raised its holdings in USANA Health Sciences by 339.6% in the first quarter. PNC Financial Services Group Inc. now owns 998 shares of the company's stock worth $27,000 after purchasing an additional 771 shares during the period. Versant Capital Management Inc raised its holdings in USANA Health Sciences by 542.5% in the first quarter. Versant Capital Management Inc now owns 1,150 shares of the company's stock worth $31,000 after purchasing an additional 971 shares during the period. Parallel Advisors LLC raised its holdings in USANA Health Sciences by 8,141.2% in the first quarter. Parallel Advisors LLC now owns 1,401 shares of the company's stock worth $38,000 after purchasing an additional 1,384 shares during the period. US Bancorp DE raised its holdings in USANA Health Sciences by 13.1% in the first quarter. US Bancorp DE now owns 4,611 shares of the company's stock worth $124,000 after purchasing an additional 535 shares during the period. Finally, Public Employees Retirement System of Ohio raised its holdings in USANA Health Sciences by 635.5% in the fourth quarter. Public Employees Retirement System of Ohio now owns 5,075 shares of the company's stock worth $182,000 after purchasing an additional 4,385 shares during the period. 54.25% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of USANA Health Sciences from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Two analysts have rated the stock with a Hold rating, According to data from MarketBeat, USANA Health Sciences has an average rating of "Hold" and an average price target of $36.00.

Insider Activity at USANA Health Sciences

In related news, COO Walter Noot sold 6,291 shares of the firm's stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $30.29, for a total value of $190,554.39. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gilbert A. Fuller sold 1,058 shares of the firm's stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $29.10, for a total transaction of $30,787.80. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 11,364 shares of company stock valued at $342,536. Corporate insiders own 0.63% of the company's stock.

USANA Health Sciences Stock Up 0.4%

Shares of NYSE:USNA traded up $0.1150 during midday trading on Wednesday, reaching $31.0650. 101,154 shares of the company were exchanged, compared to its average volume of 177,321. USANA Health Sciences, Inc. has a fifty-two week low of $23.10 and a fifty-two week high of $41.83. The stock has a fifty day simple moving average of $30.91 and a two-hundred day simple moving average of $29.55. The firm has a market cap of $567.62 million, a PE ratio of 17.26, a P/E/G ratio of 0.96 and a beta of 0.61.

USANA Health Sciences (NYSE:USNA - Get Free Report) last released its earnings results on Tuesday, July 22nd. The company reported $0.74 earnings per share for the quarter, beating analysts' consensus estimates of $0.54 by $0.20. The business had revenue of $235.85 million during the quarter, compared to the consensus estimate of $225.20 million. USANA Health Sciences had a net margin of 3.79% and a return on equity of 9.48%. USANA Health Sciences has set its FY 2025 guidance at 2.350-3.000 EPS. As a group, analysts forecast that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current year.

USANA Health Sciences Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.